 |
市场调查报告书
商品编码
1772631
美国的生物相似药的公共卫生支出:资料主导的分析US Public Health Spending on Biosimilars: A Data Driven Analysis |
||||||
本报告全面分析了生物相似药对美国公共卫生支出的影响，特别关注联邦医疗保险（Medicare）和医疗补助（Medicaid）。报告深入探讨了生物相似药的审批、上市和应用动态，并深入分析了这些因素如何影响药品支出。透过分析来自医疗保险和医疗补助服务中心 (CMS) 和美国食品药物管理局 (FDA) 的数据，报告评估了生物相似药与原厂生物製剂的成本效益，并重点分析了生物相似药製造商的价格差异和收益表现。
此外，报告还探讨了生物相似药处方对患者获得药物和医疗保健成本的影响，并展望了随着更多生物製剂专利到期而可能出现的市场变化。对于希望了解美国公共卫生体系中生物相似药发展格局的製药专业人士而言，本分析至关重要。
关键问题
- 1.生物相似药如何影响联邦医疗保险（Medicare）和医疗补助（Medicaid）的药品支出？
- 2.美国公共医疗体系中生物相似药的采用现况如何？
- 3.在联邦医疗保险（Medicare）和医疗补助（Medicaid）中，生物相似药的价格与原厂药相比如何？
- 4.哪些生物相似药製造商在公共报销体系中创造了最多的收入？
- 5.生物相似药对每张处方中生物製剂的支出削减效果如何？
- 6.生物相似药的可近性如何影响联邦医疗保险（Medicare）和医疗补助（Medicaid）的患者数量？
- 7.评估美国公共医疗体系中生物相似药绩效的关键指标是什么？
- 8.联邦医疗保险B部分和D部分中生物相似药的报酬有何不同？
- 9.随着许多生物製剂的专利到期，新的生物相似药的预期影响是什么？
- 10.本报告如何使用CMS数据来评估生物相似药的采用与支出？
主要企业
|
|
调查手法
本报告基于独立、简洁的分析，该分析源自于专有的产业研究以及对产业意见领袖的深入访谈。这些报告深入分析了製药企业高管需要了解的关键发展和市场趋势，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这些初步研究，我们制定了基于证据、专家意见的讨论指南，以确保研究能够解答最重要的问题。此外，我们制定了严格的筛选标准，以确保受访者拥有足够的经验、知识和资格就该主题发表意见。
我们的报告有何独特之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助您掌握新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家独家访谈和数据，以及持续的市场监测，让您全面洞察市场动态。我们的报告涵盖 40 多个活跃疾病领域，汇集医生情报（包括 KOL 洞察和定量医生调查），以及行业专家对医疗事务、数位医疗、销售与市场营销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。
This report provides a comprehensive analysis of the impact of biosimilars on US public health spending, specifically focusing on Medicare and Medicaid. It delves into the dynamics of biosimilar approvals, launches and uptake, offering insights into how these factors influence pharmaceutical expenditure. By examining data from the Centers for Medicare and Medicaid Services (CMS) and the FDA, the report evaluates the cost effectiveness of biosimilars compared to originator biologics, highlighting price differences and revenue achievements of biosimilar manufacturers.
Additionally, it explores the implications of biosimilar prescribing on patient access and healthcare costs, providing a forward-looking perspective on the potential market shifts as more biologic patents expire. This analysis is essential for pharmaceutical professionals seeking to understand the evolving landscape of biosimilars within the US public health system.
Key Questions Answered:
- 1. How have biosimilars impacted pharmaceutical expenditure under Medicare and Medicaid?
- 2. What is the current level of biosimilar uptake in the US public health system?
- 3. How do biosimilar and originator product prices compare within Medicare and Medicaid?
- 4. Which biosimilar manufacturers have achieved the greatest revenues in the public reimbursement system?
- 5. What is the effect of biosimilar prescribing on reducing expenditure for biologic products?
- 6. How has the availability of biosimilars influenced patient numbers under Medicare and Medicaid?
- 7. What are the key metrics used to assess biosimilar performance in the US public health system?
- 8. How do Medicare Part B and Part D differ in terms of biosimilar reimbursement?
- 9. What is the projected impact of newer biosimilars as more biologic patents expire?
- 10. How does the report utilise CMS data to evaluate biosimilar uptake and expenditure?
Key Companies:
|
|
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
